USA. DEA and HHS Issue Final Telemedicine Rule for Buprenorphine Access The Drug Enforcement Administration (DEA), together with the Department of Health and Human Services (HHS), finalized telemedicine flexibility regulations for the p...

„Leitfaden für Angehörige der Heilberufe“ - Zur Schulung und Unterstützung der Anwendung von Nyxoid® (Naloxon) Bereitstellung kurzer Informationen für Angehörige der Heilberufe über Nyxoid ® (Naloxon Nasenspray-Lösung) Unterstützung von Angehöri...

USA. Community Opioid Overdose Reversal Medications (OORMs) Planning Toolkit  This comprehensive resource is designed to help communities expand access to lifesaving medications like naloxone to reduce overdose fatalities. The toolkit provid...

Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia. Arlene Martínez-Rivera et al. Sci. Adv.10,eadq4779(2024).DOI:10.1126/sciadv.adq4779 https://www.science.org/doi/10.1126/sciadv.adq4779

Trends in Treatment Need and Receipt for Substance Use Disorders in the US.  Liu L, Zhang C, Nahata MC.  JAMA Netw Open. 2025;8(1):e2453317. doi:10.1001/jamanetworkopen.2024.53317 https://jamanetwork.com/journals/jamane...

The first five years of implementing Missouri's medication first approach to opioid use disorder treatment: Plateaus, regressions, and underbellies of progress.  Winograd RP, Park B, Coffey B, Ghonasgi R, Blanchard B, Thater P, Brown KC.&nbs...